Home
About Us
Services
Latest News
- Posts
Contact
Sign In

Skip to content

Home
About Us
Services
Latest News
- Posts
Contact
Sign In

Nothing Found

Sorry, but nothing matched your search terms. Please try again with some different keywords.

Search for:

Latest News

Neurocrine and BIAL Announce Exclusive North American Licensing Agreement of Opicapone for $145M
August 13, 2017, Healthcare
Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion
August 13, 2017, Healthcare
FDA accepts Merck application for lung cancer combo therapy
August 10, 2017, Healthcare
Gundlach: ‘trouble’ for U.S. stocks if 10-year yield hits above 3 percent
August 10, 2017, Finance
Wall Street Is Starting to Get Nervous About All the Money Pouring Into U.S. Stocks
January 9, 2017, Finance

Neurocrine and BIAL Announce Exclusive North American Licensing Agreement of Opicapone for $145M
Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion
FDA accepts Merck application for lung cancer combo therapy
Gundlach: ‘trouble’ for U.S. stocks if 10-year yield hits above 3 percent
Wall Street Is Starting to Get Nervous About All the Money Pouring Into U.S. Stocks

Home
About Us
Services
Latest News
Contact
Sign In

© 2015 Biocoast Capital